OS Therapies (OSTX) said Monday it has formed OS Drug Conjugates unit and initiated a review of strategic options for its tunable antibody-drug conjugates and other tunable drug conjugates platforms.
The biotechnology company said it has started talks with antibody-drug conjugates therapeutics companies in the US, China, and other jurisdictions for potential joint ventures that will be spun off into standalone public companies.
Shares of the company rose more than 8% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.